A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis

In-Depth Analysis
Expert Opinions

Expert Opinions
Funding & IPOs

Funding & IPOs
Clinical Results & Milestones

Clinical Results & Milestones
EDITOR’S PICKS
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
The Reporter Newsletter
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 launch
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 launch
Watch Now
Recent clinical developments offer hope for immunosuppression-free diabetes treatment while raising serious questions about safety in gene therapy for muscular …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Recommended Post
Listen Now
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory vaccines.
Longstanding trend of mega-rounds continues as February sees billions channeled into companies advancing therapies for oncology, rare diseases, and next-gen discovery platforms.
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Ready To Explore Industry News?
All articles are free -no payment or registration required.





























